Sort by
Refine Your Search
-
. They will work closely with the wider project team to ensure that survivor perspectives shape the research process and outcomes, and will contribute to dissemination through academic publications, conferences
-
(myofiber) handling Experience in handling, processing, analysing and interpreting large data sets Experience in mentoring, leading and organising junior laboratory members and laboratory arrangements (e.g
-
analysing qualitative data, and leading on the development of the theoretical framework. They will work closely with the wider project team to ensure that survivor perspectives shape the research process and
-
will increase to Grade 6. Desirable criteria Experience with skeletal muscle tissue and single muscle cell (myofiber) handling Experience in handling, processing, analysing and interpreting large data
-
document will provide information of what criteria will be assessed at each stage of the recruitment process. Please note that this is a PhD level role but candidates who have submitted their thesis and are
-
involvement and engagement (PPIE) processes, with experience contributing to or evaluating PPIE activities. Experience in/understanding of eye-tracking and/or EEG data acquisition and analysis (e.g. Brain
-
information of what criteria will be assessed at each stage of the recruitment process. * Please note that this is a PhD level role but candidates who have submitted their thesis and are awaiting award
-
collaboratively as part of a research team, with strong organisational and time management skills. Desirable criteria Understanding of patient and public involvement and engagement (PPIE) processes, with experience
-
these projections with observational data, and compare the results with those from other emulators of similar datasets (e.g. Gaussian Process methods by the project lead). These results will inform the IPCC AR7, and
-
inflammatory diseases and exploring immunotherapy to treat them. This exciting project involves characterising samples from a recently completed Phase II clinical trial for amyotrophic lateral sclerosis (ALS